Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery. The NAPA Trial

Journal of the American College of Cardiology

Volumn 49, Issue 6, 2007, Pages 716-726

  Mentzer Jr , Robert M ^a   Oz, Mehmet C ^b   Sladen, Robert N ^b   Graeve, Allen H ^c   Hebeler Jr , Robert F ^d   Luber Jr , John M ^e   Smedira, Nicholas G ^f  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

^c Tacoma General Hospital   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e Franciscan Health System   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMRINONE; ANGIOTENSIN RECEPTOR ANTAGONIST; APROTININ; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; EPHEDRINE; ETACRYNIC ACID; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; NICARDIPINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENYLEPHRINE; TORASEMIDE; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ADULT; ANESTHESIA INDUCTION; ARTICLE; ATELECTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERIOPERATIVE PERIOD; PERIPHERAL EDEMA; PLEURA EFFUSION; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK ASSESSMENT; SINUS TACHYCARDIA; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; TREATMENT OUTCOME; URINE VOLUME;

ADULT; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PERIOPERATIVE CARE; PROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33846844802     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.10.048     Document Type: Article

References (33)

1. Butler J., Emerman C., Peacock W.F., Mathur V.S., and Young J.B. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant 19 (2004) 391-399
2. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
3. Mills R.M., LeJemtel T.H., Horton D.P., et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 34 (1999) 155-162
4. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
5. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4 (1998) 37-44
6. Aronson D., and Burger A.J. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 90 (2002) 435-438
7. Beaver T.M., Winterstein A.G., Shuster J.J., et al. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin Cardiol 29 (2006) 18-24
8. Feldman D.S., Ikonomidis J.S., Uber W.E., et al. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 10 (2004) 292-296
9. Salzberg S.P., Filsoufi F., Anyanwu A., et al. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 80 (2005) 502-506
10. Mangano C.M., Diamondstone L.S., Ramsay J.G., Aggarwal A., Herskowitz A., and Mangano D.T. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 128 (1998) 194-203
11. Burns K.E.A., Chu M.W.A., Novick R.J., et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. JAMA 294 (2005) 342-350
12. Conlon P.J., Stafford-Smith M., White W.D., et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 14 (1999) 1158-1162
13. Loef B.G., Epema A.H., Smilde T.D., et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol 16 (2005) 195-200
14. Cooper W.A., O'Brien S.M., Thourani V.H., et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 113 (2006) 1063-1070
15. Heywood J.T., Fonarow G.C., and Wynne J. Is heart failure really renal failure?. Observations from 88,075 admissions with decompensated heart failure in the ADHERE Registry. (abstr). J Am Coll Cardiol 45 Suppl A (2005) 173A
16. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., and Boscardin W.J. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
17. Bove T., Landoni G., Calabrò M.G., et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 111 (2005) 3230-3235
18. Lassnigg A., Donner E., Grubhofer G., Presterl E., Druml W., and Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 11 (2000) 97-104
19. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
20. Hillis G.S., Croal B.L., Buchan K.G., et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 113 (2006) 1056-1062
21. Lazar H.L., Fitzgerald C., Gross S., Heeren T., Aldea G.S., and Shemin R.J. Determinants of length of stay after coronary artery bypass graft surgery. Circulation 92 Suppl (1995) II20-II24
22. Sezai A., Shiono M., Orime Y., et al. Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 69 (2000) 732-738
23. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., and Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37 (2001) 1221-1227
24. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., and Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 76 (1993) 91-96
25. Jensen K.T., Carstens J., and Pedersen E.B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 274 (1998) F63-F72
26. Jensen K.T., Eiskjaer H., Carstens J., and Pedersen E.B. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond) 96 (1999) 5-15
27. Yancy C.W., Saltzberg M.T., Berkowitz R.L., et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the Fusion I trial). Am J Cardiol 94 (2004) 595-601
28. Yasue H., and Yoshimura M. Natriuretic peptides in the treatment of heart failure. J Card Fail 2 Suppl (1996) S277-S285
29. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
30. Marcus L.S., Hart D., Packer M., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94 (1996) 3184-3189
31. Wang D.J., Dowling T.C., Meadows D., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110 (2004) 1620-1625
32. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
33. Sica D.A., Gottwald M., and Li Y.-P. Nesiritide appears to inhibit the rise in plasma aldosterone associated with furosemide diuresis. (abstr). J Card Fail 12 Suppl 1 (2006) S85-S86